title: Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.
abstract: Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatment.
authors.affiliation: Department of Cutaneous and Venereal Diseases and Plastic Surgery, Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy. antoniorichetta@hotmail.com
authors.forename: Antonio Giovanni
authors.initials: AG
authors.lastname: Richetta
authors.forename: Elisa
authors.initials: E
authors.lastname: Maiani
authors.forename: Valentina
authors.initials: V
authors.lastname: Carlomagno
authors.forename: Valentina
authors.initials: V
authors.lastname: Carboni
authors.forename: Carlo
authors.initials: C
authors.lastname: Mattozzi
authors.forename: Simona
authors.initials: S
authors.lastname: Giancristoforo
authors.forename: Stefano
authors.initials: S
authors.lastname: Calvieri
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage; D003873:Dermatitis, Exfoliative / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011565:Psoriasis / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000068879:Adalimumab; C100416:peginterferon alfa-2a